Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer...

Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are...

the production team that produced Sipuleucel-T developed by Dendreon and the Immune Response Corporation. Whether T cells are genetically engineered or...

after the vaccine is delivered. The best known dendritic cell vaccine is Sipuleucel-T (Provenge), which only improved survival by four months. The efficacy...

hypertension, diabetes, cancer, or autoimmune disease.[citation needed] Sipuleucel-T is the first DCs- based cancer vaccine for men with asymptomatic or minimally...

biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of...

approved by USA Food and Drug Administration, as following; Provenge is Sipuleucel-T, a dendritic cell based vaccine for prostate cancer. Bacillus Calmettle-Guerin...

inhibitor abiraterone acetate. An alternative is the cell therapy procedure Sipuleucel-T, where the affected person's immune cells are removed, treated to more...

L03AX15 Mifamurtide L03AX16 Plerixafor L03AX17 Sipuleucel-T L03AX18 Cridanimod L03AX19 Dasiprotimut-T L03AX21 Elapegademase L03AX22 Leniolisib QL03AX90...

of cancer treatment research include: Anti-cancer vaccines Oncophage Sipuleucel-T (Provenge) is a prostate cancer vaccine Inactivated tumor cells are investigated...

number of tumors, notably malignant melanoma and renal cell carcinoma. Sipuleucel-T is a vaccine-like strategy for prostate cancer in which dendritic cells...

O, Salama A. Kantoff P.W., Higano C.S., Shore N.D.; et al. (2010). "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer". N Engl J Med...

also served as the lead investigator for Dendreon's clinical trials for Sipuleucel-T, a therapeutic vaccine for prostate cancer approved in 2010. After 28...

topotecan for chemotherapy of cancer 2010  – US FDA approves immunotherapy, sipuleucel-T dendritic cell vaccine for advanced prostate cancer 2010  – China advances...

sipatrigine (INN) siplizumab (INN) sipoglitazar (USAN) siponimod (INN) sipuleucel-T (USAN) siratiazem (INN) sirolimus (INN) sirukumab (INN) sisomicin (INN)...

that invention, Sipuleucel-T, more commonly known as Provenge, became the first FDA-approved immunotherapeutic cancer vaccine. Sipuleucel-T, initially approved...

PMC 10355925. PMID 26024831. S2CID 10625154. Slovin SF (29 September 2015). "Sipuleucel-T - A Model for Immunotherapy Trial Development". In Mydlo JH, Godec CJ...

Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2). GCO 09–1509. An open label study of sipuleucel-T in men with...

Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2)...

released or are undergoing clinical trial. FDA-approved vaccines, such as Sipuleucel-T for metastasizing prostate cancer or Nivolumab for melanoma and lung...

pp. 432. ISBN 9780199334414. immune response corporation kimberlin. "Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine". Drugs in R&D. 7 (3): 197–201...

Responses for the 2010 PLI at Dendreon's Manufacturing Facility for Sipuleucel-T at Morris Plains, New Jersey - Provenge". U.S. Food and Drug Administration...

in April 2009 and is supported by Cougar Biotechnology. A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June...